Analysis Note
Positive ControlIMR5 cells
Application
Frozen Sections (1-5 µg/ml)r>Immunoblotting (1-5 µg/ml, see application references)r>Immunofluorescence (1-5 µg/ml, see application references)r>Immunoprecipitation (1-2 µg/sample, see application references)
General description
Purified mouse monoclonal antibody generated by immunizing BALB/c mice with specified immunogen and fusing splenocytes with SP2/0 mouse myeloma cells (see application references). Recognizes N-myc and its cleavage products.
Recognizes the N-myc protein and its cleavage product in IMR5 cells.
This Anti-N-Myc Mouse mAb (NCM II 100) is validated for use in Frozen Sections, Immunoblotting, Immunofluorescence, Immunoprecipitation for the detection of N-Myc.
Immunogen
recombinant, human, N-myc fusion protein, expressed in E. coli
Human
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Other Notes
Brondyk, W.H. 1991. Oncogene6, 1269.Ikegaki, N., et al. 1988. Adv. Neuroblastoma Research.2, 133.LeGouy, E., et al. 1987. In Nuclear Oncogenes, Cold Spring Harbor Laboratory, 144.Cole, M.D., 1986. Ann. Rev. Gen.20, 361.Ikegaki, N., et al. 1986. Proc. Natl. Acad. Sci. USA83, 5929.Slamon, D.J., et al. 1986. Science232, 768.Seeger, R.C., et al. 1985. New Engl. J. Med.313, 1111.Brodeur, G.M., et al. 1984. Science224, 1121.Michitsch, R.W., et al. 1984. Mol. Cell. Biol.11, 2370.Kohl, N.E., et al. 1983. Cell35, 603.Schwab, M., et al. 1983. Nature305, 245.
It is important to compensate for the short half life of this protein when preparing tissue sections or extracts. We recommended that all preparations be kept cold and that a cocktail of protease inhibitors be used. Antibody should be titrated for optimal results in individual systems.
Packaging
100 µg in Plastic ampoule
Please refer to vial label for lot-specific concentration.
Physical form
In 50 mM sodium phosphate buffer, 50% glycerol.
Reconstitution
Following initial thaw, aliquot and freeze (-20°C).
Warning
Toxicity: Standard Handling (A)
This product has met the following criteria: